159 related articles for article (PubMed ID: 12394688)
1. Management of post-chemotherapy residual masses in advanced seminoma.
Flechon A; Bompas E; Biron P; Droz JP
J Urol; 2002 Nov; 168(5):1975-9. PubMed ID: 12394688
[TBL] [Abstract][Full Text] [Related]
2. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
3. Surgery for a post-chemotherapy residual mass in seminoma.
Herr HW; Sheinfeld J; Puc HS; Heelan R; Bajorin DF; Mencel P; Bosl GJ; Motzer RJ
J Urol; 1997 Mar; 157(3):860-2. PubMed ID: 9072586
[TBL] [Abstract][Full Text] [Related]
4. [Management of advanced seminoma: retrospective study of 96 patients].
Bompas E; Fléchon A; Biron P; Droz JP
Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
[TBL] [Abstract][Full Text] [Related]
5. Postchemotherapy residual masses in advanced seminoma: current management and outcomes.
Quek ML; Simma-Chiang V; Stein JP; Pinski J; Quinn DI; Skinner DG
Expert Rev Anticancer Ther; 2005 Oct; 5(5):869-74. PubMed ID: 16221056
[TBL] [Abstract][Full Text] [Related]
6. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
Puc HS; Heelan R; Mazumdar M; Herr H; Scheinfeld J; Vlamis V; Bajorin DF; Bosl GJ; Mencel P; Motzer RJ
J Clin Oncol; 1996 Feb; 14(2):454-60. PubMed ID: 8636757
[TBL] [Abstract][Full Text] [Related]
7. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
Fosså SD; Droz JP; Stoter G; Kaye SB; Vermeylen K; Sylvester R
Br J Cancer; 1995 Mar; 71(3):619-24. PubMed ID: 7880748
[TBL] [Abstract][Full Text] [Related]
9. Residual mass following chemotherapy of seminoma.
Horwich A; Paluchowska B; Norman A; Huddart R; Nicholls J; Fisher C; Husband J; Dearnaley DP
Ann Oncol; 1997 Jan; 8(1):37-40. PubMed ID: 9093705
[TBL] [Abstract][Full Text] [Related]
10. The management of residual masses after chemotherapy in metastatic seminoma.
Ravi R; Ong J; Oliver RT; Badenoch DF; Fowler CG; Hendry WF
BJU Int; 1999 Apr; 83(6):649-53. PubMed ID: 10233573
[TBL] [Abstract][Full Text] [Related]
11. The significance of resections for residual masses after chemotherapy in metastatic testicular tumors.
Suzuki K; Orikasa S; Hoshi S; Yoshikawa K; Saito S; Ohyama C; Sato M; Kawamura S; Numahata K; Ito A; Tokuyama S
Int J Urol; 1999 Jun; 6(6):305-13. PubMed ID: 10404307
[TBL] [Abstract][Full Text] [Related]
12. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.
Hartmann JT; Schmoll HJ; Kuczyk MA; Candelaria M; Bokemeyer C
Ann Oncol; 1997 Jun; 8(6):531-8. PubMed ID: 9261521
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection.
Hofmockel G; Gruss A; Theiss M
Urol Int; 1996; 57(1):38-42. PubMed ID: 8840489
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
[TBL] [Abstract][Full Text] [Related]
15. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
16. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
17. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
18. [Retroperitoneal residual tumor resection after chemotherapy of malignant testicular cancers].
Albers P
Aktuelle Urol; 2012 May; 43(3):197-206. PubMed ID: 22639031
[No Abstract] [Full Text] [Related]
19. Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions.
Giannis M; Aristotelis B; Vassiliki K; Ioannis A; Konstantinos S; Nikolaos A; Georgios P; Georgios P; Pantelis P; Meletios-Athanasios D
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1495-500. PubMed ID: 19437039
[TBL] [Abstract][Full Text] [Related]
20. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy.
Motzer R; Bosl G; Heelan R; Fair W; Whitmore W; Sogani P; Herr H; Morse M
J Clin Oncol; 1987 Jul; 5(7):1064-70. PubMed ID: 3598610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
